Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease of 2019 (COVID-19) that emerged in December 2019 in Wuhan, China, and rapidly spread worldwide, with a daily increase in confirmed cases and infection-related deaths. The World Health Organization declared a pandemic on the 11th of March 2020. COVID-19 presents flu-like symptoms that become severe in high-risk medically compromised subjects. The aim of this study was to perform an updated overview of the treatments and adjuvant protocols for COVID-19. Methods: A systematic literature search of databases was performed (MEDLINE PubMed, Google Scholar, UpToDate, Embase, and Web of Science) using the keywords: “COVID-19”, “2019-nCoV”, “coronavirus” and “SARS-CoV-2” (date range: 1 January 2019 to 31st October 2020), focused on clinical features and treatments. Results: The main treatments retrieved were antivirals, antimalarials, convalescent plasma, immunomodulators, corticosteroids, anticoagulants, and mesenchymal stem cells. Most of the described treatments may provide benefits to COVID-19 subjects, but no one protocol has definitively proven its efficacy. Conclusions: While many efforts are being spent worldwide in research aimed at identifying early diagnostic methods and evidence-based effective treatments, mass vaccination is thought to be the best option against this disease in the near future.

The 15-months clinical experience of sars-cov-2: A literature review of therapies and adjuvants / A.D. Inchingolo, G. Dipalma, A.M. Inchingolo, G. Malcangi, L. Santacroce, M.T. D'oria, C.G. Isacco, I.R. Bordea, S. Candrea, A. Scarano, B. Morandi, M.D. Fabbro, M. Farronato, G.M. Tartaglia, M.G. Balzanelli, A. Ballini, L. Nucci, F. Lorusso, S. Taschieri, F. Inchingolo. - In: ANTIOXIDANTS. - ISSN 2076-3921. - 10:6(2021), pp. 881.1-881.43. [10.3390/antiox10060881]

The 15-months clinical experience of sars-cov-2: A literature review of therapies and adjuvants

B. Morandi;M. Farronato;G.M. Tartaglia;S. Taschieri;
2021

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease of 2019 (COVID-19) that emerged in December 2019 in Wuhan, China, and rapidly spread worldwide, with a daily increase in confirmed cases and infection-related deaths. The World Health Organization declared a pandemic on the 11th of March 2020. COVID-19 presents flu-like symptoms that become severe in high-risk medically compromised subjects. The aim of this study was to perform an updated overview of the treatments and adjuvant protocols for COVID-19. Methods: A systematic literature search of databases was performed (MEDLINE PubMed, Google Scholar, UpToDate, Embase, and Web of Science) using the keywords: “COVID-19”, “2019-nCoV”, “coronavirus” and “SARS-CoV-2” (date range: 1 January 2019 to 31st October 2020), focused on clinical features and treatments. Results: The main treatments retrieved were antivirals, antimalarials, convalescent plasma, immunomodulators, corticosteroids, anticoagulants, and mesenchymal stem cells. Most of the described treatments may provide benefits to COVID-19 subjects, but no one protocol has definitively proven its efficacy. Conclusions: While many efforts are being spent worldwide in research aimed at identifying early diagnostic methods and evidence-based effective treatments, mass vaccination is thought to be the best option against this disease in the near future.
SARS-CoV-2 (COVID-19); vaccines; anticoagulants; antioxidants; antivirals; antimalarials; immunotherapy; immunomodulators; corticosteroids; autologous stem cells
Settore MED/50 - Scienze Tecniche Mediche Applicate
Settore MED/28 - Malattie Odontostomatologiche
Article (author)
File in questo prodotto:
File Dimensione Formato  
antioxidants 2021-10-00881-Inchingolo.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 4.74 MB
Formato Adobe PDF
4.74 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/861129
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact